Benefits
Sleep onset (inconsistent evidence)
Evidence that valerian shortens the time to fall asleep is mixed. Some trials and older meta-analyses report a modest benefit, but the most rigorous randomized trials, including one in older women with insomnia, found no measurable effect on sleep latency or sleep quality by polysomnography or actigraphy. Any benefit appears small and inconsistent, and valerian can itself cause morning grogginess in some people.
Calming effect (preliminary anxiety evidence)
Valerenic acid acts on GABA-A receptors, part of the same calming system targeted by anti-anxiety drugs, which is the proposed basis for a relaxing effect. A meta-analysis pooling eight anxiety studies suggested valerian may reduce anxiety, but those trials were few, of low and variable quality, and often used combination products, so the anxiety evidence is preliminary. No cited trial compared valerian directly against a benzodiazepine.
Stress relief
Valerian is traditionally taken for relaxation, and its GABA-related mechanism is the proposed basis for a calming effect. There are no cited human trials measuring cortisol, heart rate variability, or a stress-buffering outcome for valerian, so this use rests on tradition and mechanism rather than on measured stress endpoints.
Menopausal symptom support
Two small randomized trials in menopausal women in Iran reported that valerian reduced the frequency and severity of hot flashes compared with placebo. The evidence is limited to these small single-country trials, so the effect on menopausal symptoms should be considered preliminary.
Mechanism of action
GABA-A receptor modulation
Valerenic acid binds GABA-A receptor beta subunits as a positive allosteric modulator — similar mechanism to benzodiazepines but with lower affinity and without dependency risk.
GABA transaminase inhibition
Valerian extract inhibits GABA-T, the enzyme responsible for breaking down GABA in the synaptic cleft, increasing GABA availability and duration of action in the CNS.
Adenosine receptor interaction
Some valerian constituents (hesperidin, linarin) act on adenosine A1 receptors, which mediate sleep pressure and sedation as part of the natural sleep-wake regulatory system.
Clinical trials
Pooled analysis of 16 clinical trials examining valerian root extract for subjective sleep quality improvement.
1,093 patients across 16 clinical trials.
The pooled dichotomous outcome favored valerian for improved sleep quality (about 1.8 times as likely as placebo), but the authors caution this result was undermined by publication bias and methodologically weak trials. More rigorous later randomized trials found no measurable effect on sleep, so the overall evidence is inconsistent.
Clinical trial of valerian 255 mg three times daily vs. placebo in 68 postmenopausal women for 8 weeks.
68 postmenopausal women with hot flashes. 8-week intervention.
Valerian significantly reduced the severity of hot flashes compared with placebo (p<0.001) over 8 weeks, with hot flash frequency also falling during treatment and no serious adverse effects. This was a single small trial of 68 women.